Kidney Cancer Drugs Market Size, Share, and Trends 2024 to 2033

Kidney Cancer Drugs Market (By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy; By Pharmacological Class Type: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokinesis, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 4354
  • Category : Healthcare

Kidney Cancer Drugs Market Size and Growth 2024 to 2033

The global kidney cancer drugs market size was valued at USD 6.51 billion in 2023 and is anticipated to reach around USD 11.05 billion by 2033, growing at a CAGR of 5.43% from 2024 to 2033. Targeted therapy drugs, immunotherapy drugs, and chemotherapy drugs can help with the treatment of kidney cancers and contribute to the growth of the kidney cancer drugs market.

Kidney Cancer Drugs Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Kidney Cancer Drugs Market Key Takeaways

  • The North America kidney cancer drugs market size accounted for USD 2.21 billion in 2023 and is expected to attain around USD 3.81 billion by 2033, poised to grow at a CAGR of 5.59% between 2024 and 2033.
  • North America dominated the market with the largest revenue share of 34% in 2023.
  • Asia Pacific is estimated to hold the fastest-growing market over the forecast period of 2024-2033.
  • By therapy, the targeted therapy segment dominated the market in 2023.
  • By therapy, the immunotherapy segment is expected to witness the fastest growth during the forecast period.
  • By pharmacological class, the angiogenesis inhibitors segment has held the major revenue share of 52% in 2023.
  • By pharmacological class, the cytokinesis segment will grow rapidly during the forecast period.
  • By distribution channel, the hospital pharmacies segment dominated the market in 2023.
  • By distribution channel, the retail pharmacies segment is projected to see the fastest growth during the forecast period.

U.S. Kidney Cancer Drugs Market Size and Growth 2024 to 2033

The U.S. kidney cancer drugs market size was estimated at USD 1.66 billion in 2023 and is predicted to be worth around USD 2.88 billion by 2033 with a CAGR of 5.66% from 2024 to 2033.

U.S. Kidney Cancer Drugs Market Size 2024 to 2033

North America dominated the kidney cancer drugs market in 2023. Rising genetic disorders and the presence of healthcare facilities help to the growth of the market in the North American region. The United States is the leading country in the region in terms of the growth of the market for the treatment of kidney cancer.

  • In September 2023, Jardiance 10mg tablets (empagliflozin) were approved by the United States (U.S.) Food and Drug Administration (FDA) is responsible for the treatment of adults who suffer from chronic kidney disease (CKD) at the risk of progression, and it was announced by the Boehringer Ingelheim and Eli Lilly & Company.
  • In December 2023, the United States FDA approved the drug belzutifan of Merks & Co., Inc. for the treatment of kidney cancer. This is used in the treatment of renal cell carcinoma disease in that cancer cells are found in the kidney’s lining of very small tubes in the kidney.

Kidney Cancer Drugs Market Share, By Region, 2023 (%)

Asia Pacific is estimated to hold the fastest-growing kidney cancer drugs market over the forecast period of 2024-2033. The diabetic population, hypertension, and high smoking lead to the growth of kidney cancers, and the increasing number of major key manufacturers of the products contribute to the growth of the market. China, India, and Japan are the leading countries in the region for the growth of the market.

  • In October 2023, DCGI (Drug Controller General of India) approved MSD’s anti-PD one therapy, KEYTRUDA (pembrolizumab) immunotherapy, which helps the immune system fight cancer cells for the treatment of renal cell carcinoma is the common type of kidney cancer and triple-negative breast cancer in adults was announced by MSD (called as Merck in the U.S. and Canada).

Asia Pacific Kidney Cancer Drugs Market Size and Growth 2024 to 2033

The Asia Pacific kidney cancer drugs market size was calculated at USD 1.89 billion in 2023 and is projected to expand around USD 3.26 billion by 2033, poised to grow at a CAGR of 5.60% from 2024 to 2033.

Forecast Year Market Size (USD Billion)
2023 1.89
2024 1.99
2025 2.10
2026 2.21
2027 2.33
2028 2.46
2029 2.59
2030 2.73
2031 2.88
2032 3.04
2033 3.26

 

Kidney Cancer Drugs Market Overview

The kidney cancer drugs market consists of sales of kidney cancer drugs and related services by entities such as organizations, sole traders, and partnerships that produce kidney cancer drugs to diagnose and treat kidney cancer. These industries include the formation of the drugs used in targeted therapy, immunotherapy, and chemotherapy.

Kidney cancer disease is caused by the cancerous or malignant cells in the kidney. This causes extreme fever and fatigue, sudden weight loss, low back pain, lump in the abdomen, and blood in urine. These various types can be life-threatening or dangerous if untreated. There is a need for drugs for the treatment of kidney cancer. Most of the doctors prescribe medications called immunotherapy and targeted therapy. Kidney cancer drugs help the body’s immune system to eliminate and recognize cancer cells. These factors help to the growth of the kidney cancer drugs market.

Kidney Cancer Drugs Market Growth Factors

  • The kidney cancer is caused by the cancerous or malignant cells in the kidney. These can be treated by the drugs used in the therapies, including chemotherapy, immunotherapy, and targeted therapy.
  • Treatment of kidney cancer can involve the combination of targeted therapy and immunotherapy medications.
  • These kidney cancer drugs help to reduce the risk of returning cancer or slow its growth and can shrink a tumor.
  • Doctors also prescribe medications for kidney cancer treatment that are based on immunotherapy and targeted therapy.

Kidney Cancer Drugs Market Scope

Report Coverage Details
Kidney Cancer Drugs Market Growth Rate from 2024 to 2033 CAGR of 5.43%
Kidney Cancer Drugs Market Size in 2023 USD 6.51 Billion
Kidney Cancer Drugs Market Size in 2024 USD 6.86 Billion
Kidney Cancer Drugs Market Size by 2033 USD 11.05 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Therapy Type, Pharmacological Class Type, Distribution Channel, and Regions
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Kidney Cancer Drugs Market Dynamics

Drivers

Increasing senior population

As age increases, the risk of kidney cancer increases in the senior population or older age. Kidney cancer is found in the senior population more than the other. The senior population is exposed to chemicals, cigarette smoke, and sunlight, and their body can cause cancer agents instantly. Kidney cancer is more common in the senior population. This kidney cancer needs treatment with different drugs used in the therapies. This helps to the growth of the kidney cancer drugs market.

Increased risks of kidney cancer

Smoking people are the main reason for the risk of kidney cancer than the non-smoking person. People who are obese have higher risks of kidney cancer. Hypertension or high blood pressure increases kidney cancer risks. The treatment of kidney failure needs long-term dialysis, which has a high risk of kidney cancer developing. Mutation in DNA. Some people are born with specific inherited syndromes, which leads to risks of kidney cancer diseases. These risks of kidney cancer need kidney cancer drugs to treat kidney cancer. These factors help the growth of the kidney cancer drugs market.

Restraint

Side effects of kidney cancer drugs

Side effects of the kidney cancer drugs include a careful balancing act, psychological distress, blisters on the soles of the feet and palms of the hand, skin rash, easy blooding or bruising because of the low blood platelet counts, increased chance of infections because of the low white blood cell counts, hair loss, swelling in legs or arms, high blood pressure, weight loss, mouth sores, nausea and vomiting, loss of appetite, muscle or joint pain, fatigue, and diarrhea. All kidney cancer patients face the problem of psychological burden with the life-threatening disease. These side effect factors of the kidney cancer drugs can restrict the growth of the kidney cancer drugs market.

Opportunity

Advanced technologies

Advancements in immunotherapy include the combination of drugs with one another or with kidney cancer drugs or medications for the treatment of kidney cancer. Advancements in kidney cancer biomarkers and tumor profiling biomarkers for cancer characteristics help to solve the issue. Kidney subtyping and biomarkers may also help to improve the science of the therapies, including immunotherapy for kidney cancer.  Advancements in immunotherapy enhance the ability of the immune system to attack cancer cells. Immunotherapy can work in different ways based on the cells that are acting on the body. These advanced technology factors help the growth of the kidney cancer drugs market.

Therapy Insights

The targeted therapy segment dominated the kidney cancer drugs market in 2023. Kidney cancer can be treated by targeted therapy, which uses drugs to block certain proteins, genes, or molecules that fuel the growth of kidney tumors. The main two types of targeted therapy drugs are used for the treatment of kidney cancer, including monoclonal antibodies and tyrosine kinase inhibitors. Targeted therapy is more effective than the chemotherapy and immunotherapy. Most of the drugs used in the targeted therapy for the treatment of kidney cancer are angiogenesis inhibitors that disrupt the process of creating tumors by their blood vessels. These targeted therapy drugs are normally taken as tablets daily.

It also may be taken in combination with immunotherapy drugs for advanced kidney cancer as the first treatment. Targeted therapy drugs may help to treat advanced kidney cancers by slowing down or shrinking the growth of the cancer. Targeted therapy drugs can control or kill kidney cancer cells, and they help to relieve pain and control advanced kidney cancer symptoms. These factors help to the growth of the targeted therapy type segment and contribute to the growth of the market.

The immunotherapy segment is expected to witness the fastest growth in the kidney cancer drugs market during the forecast period. In the treatment of kidney cancer, immunotherapy is used to help the immune system fight off abnormal cells. The main types of immunotherapies for the treatment of kidney cancer include cytokinesis and immune checkpoint inhibitors. Immunotherapy can also be used in the treatment of advanced kidney cancer. This immunotherapy drug helps to recognize and destroy cancer cells more effectively. These factors help the growth of the immunotherapy-type segment and contribute to the growth of the market.

Pharmacological Class Insights

The angiogenesis inhibitors segment dominated the kidney cancer drugs market in 2023. For the treatment of kidney cancer drugs, angiogenesis inhibitors, including bevacizumab, axitinib, sorafenib, pazopanib, and sunitinib, are used. Some angiogenesis inhibitors are immunomodulatory drugs that suppress or stimulate the immune system, which have antiangiogenic characteristics. It helps improve overall and progression-free survival in patients who suffer from kidney cancer disease. These factors helped the growth of the angiogenesis inhibitors pharmacological class type segment and contributed to the growth of the market.

Kidney Cancer Drugs Market Share, By Pharmacological Class, 2023 (%)

The cytokinesis segment will grow rapidly in the kidney cancer drugs market during the forecast period. Cytokinesis is used in immunotherapy to treat kidney cancer. Cytokinesis plays the main role in the anticancer immune response and is the main component of the immune system. These factors help the growth of the cytokinesis pharmacological class type segment and contribute to the growth of the market.

Distribution Channel Insights

The hospital pharmacies segment dominated the kidney cancer drugs market in 2023. Hospital pharmacies have better access to patients' medical records. Improved discharge reconciliation and quality of admission by exercising oversight, a considerable contribution to safer medication use by cooperating with the other providers, offering information about possible side effects, and also checking the medicines are agreeable with existing medicines. Increased interaction with health professionals and prescribers helps to the growth of the market. Enhancing the reduction of readmission, continuity of care, and medication adherence. These factors help the growth of the hospital pharmacies distribution channel type segment and contribute to the growth of the market.

The retail pharmacies segment is projected to see the fastest growth during the forecast period. Retail pharmacies have direct access to pharmacists, which allows for personalized consultations by walk-in interactions with the pharmacists. Collaboration with the healthcare providers, and specialists, and contributing to the more comprehensive approach for patient care. It helps with one-stop shopping and saves time and effort. These factors help the growth of the retail pharmacies distribution channel type segment and contribute to the growth of the market.

Kidney Cancer Drugs Market Recent Developments

  • In December 2023, for the treatment of metastatic kidney cancer, the use of belzutifan was approved by the FDA and developed by a UTSW spinoff at UT Southwestern Medical Center.
  • In January 2024, Bristol Myers Squibb published a hypodermic or skin version of its PD-1 inhibitor Opdivo data in kidney cancer as the I-O battle heads to a new front.
  • In May 2024, Alectinib, an adjuvant treatment for lung cancer was approved by the Food and Drug Administration.

Kidney Cancer Drugs Market Companies

  • Abbvie
  • Arlak Biotech
  • Apikos Pharma
  • Astellas Pharma
  • AstraZeneca plc
  • Amgen Inc
  • Allena Pharmaceuticals
  • AVEO Oncology
  • AID Genomics Limited
  • AQVIDA GmbH
  • BIOPHARMA-MEA
  • Biogen Inc
  • Biocad
  • Baxter International Inc
  • BeiGene
  • Byer AG
  • Cure Tech Ltd.
  • Celnova Pharma
  • Celon Pharma
  • CARsgen Therapeutics
  • CStone Pharma
  • Daiichi Pharmaceutical Sankyo
  • Euroferma Laboratories S.A.
  • Enteris BioPharma
  • Emisphere Technologies, Inc.
  • Eli Lilly and Company
  • EUSA Pharma Inc
  • GlaxoSmithKline plc
  • Healthkind Labs Pvt. Ltd
  • JW Therapeutics
  • Johnson & Johnson
  • Julphar
  • Kitov Pharma Limited
  • Kolaz Biotech
  • Merck and Co., Inc.
  • Neopharma
  • Novo Nordisk A/S
  • Natco Pharma
  • NeoTX
  • Otsuka Pharmaceuticals Co., Ltd
  • Pierre Fabre Group
  • SwisscheM Healthcare Pvt. Ltd
  • TUTEUR Argentina
  • Teva Pharmaceutical Industries Ltd.
  • Rani Therapeutics
  • UroGen Pharma Ltd
  • Veropharm

Segments Covered in the Report

By Therapy Type

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

By Pharmacological Class Type

  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokinesis
  • Others (Immune Checkpoint Inhibitors, CTLA-4 Inhibitors, Antimetabolites, and Others)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The global kidney cancer drugs market size is expected to increase USD 11.05 billion by 2033 from USD 6.51 billion in 2023.

The global kidney cancer drugs market will register growth rate of 5.43% between 2024 and 2033.

The major players operating in the kidney cancer drugs market are Abbvie, Arlak Biotech, Apikos Pharma, Astellas Pharma, AstraZeneca plc, Amgen Inc, Allena Pharmaceuticals, AVEO Oncology, AID Genomics Limited, AQVIDA GmbH, BIOPHARMA-MEA, Biogen Inc, Biocad, Baxter International Inc, BeiGene, Byer AG, Cure Tech Ltd., Celnova Pharma, Celon Pharma, CARsgen Therapeutics, CStone Pharma, Daiichi Pharmaceutical Sankyo, Euroferma Laboratories S.A., Enteris BioPharma, Emisphere Technologies, Inc, and Others.

The driving factors of the kidney cancer drugs market are the increasing senior population and increased risks of kidney cancer.

North America region will lead the global kidney cancer drugs market during the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Kidney Cancer Drugs Market 

5.1. COVID-19 Landscape: Kidney Cancer Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Kidney Cancer Drugs Market, By Therapy Type

8.1. Kidney Cancer Drugs Market Revenue and Volume, by Therapy Type, 2024-2033

8.1.1 Targeted Therapy

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Immunotherapy

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Chemotherapy

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Kidney Cancer Drugs Market, By Pharmacological Class Type

9.1. Kidney Cancer Drugs Market Revenue and Volume, by Pharmacological Class Type, 2024-2033

9.1.1. Angiogenesis Inhibitors

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. mTOR Inhibitors

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Cytokinesis

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Others (Immune Checkpoint Inhibitors, CTLA-4 Inhibitors, Antimetabolites, and Others)

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Kidney Cancer Drugs Market, By Distribution Channel 

10.1. Kidney Cancer Drugs Market Revenue and Volume, by Distribution Channel, 2024-2033

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Kidney Cancer Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 12. Company Profiles

12.1. Abbvie

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Arlak Biotech

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Apikos Pharma

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Astellas Pharma

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. AstraZeneca plc

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Amgen Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Allena Pharmaceuticals

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AVEO Oncology

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AID Genomics Limited

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AQVIDA GmbH

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client